( ral and intravenousADP receptor antago...)Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis,Health
Portola Pharmaceuticals Announces Positive Data from a Phase II,Study of its Factor Xa Inhibitor at the XXI Congress of the,International Society on Thrombosis and Haemostasis
ral and intravenous
ADP receptor antagonist being developed for patients with acute
coronary syndrome (ACS), for the prevention of cardiovascular
events in patients undergoing percutaneous coronary intervention
(PCI) and for secondary prevention of MI and stroke, and for other
vascular diseases. PRT060128 is expected to enter Phase II clinical
development in the second half of 2007.
CONTACT: Dan Budwick, BMC Communications, +1-212-477-9007
x14